GLIA-CTN: Measuring Function in Children with Leukodystrophy
Jun 26, 2026 ·
2m 8s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
New research from the Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN). This summary is based on a paper published in the journal Developmental Medicine & Child Neurology on April 30,...
show more
New research from the Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN). This summary is based on a paper published in the journal Developmental Medicine & Child Neurology on April 30, 2026, titled "Performance outcomes of the PEDI-CAT for assessing functional ability in the population with leukodystrophy."
Read the paper here.
Learn more about GLIA-CTN.
Transcript:
New research from the Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN), a research group of the Rare Diseases Clinical Research Network.
Measuring Function in Children with Leukodystrophy.
This summary is based on a paper published in the journal Developmental Medicine & Child Neurology on April 30, 2026.
Leukodystrophies are a complex, often progressive group of disorders affecting the white matter of the brain due to the loss or absence of myelin, the protective coating around nerves. Although all leukodystrophies affect neurological function, the severity and speed of progression can be very different among different types.
In this study, researchers evaluated a tool to measure function in children with leukodystrophy. Ninety-nine caregivers completed four domains (daily activities, mobility, social/cognitive, and responsibility) of a parent-reported assessment called the Pediatric Evaluation of Disability Index-Computer Adapted Test (PEDI-CAT). Researchers compared the results of the daily activities and mobility domains with clinician-administered assessments, including grasp and visual motor integrations subtests, of the Peabody Developmental Motor Scale (PDMS-2) and the 88-item Gross Motor Function Measure (GMFM-88).
Results showed a strong agreement between the PEDI-CAT and the above standard assessments. This suggests that the PEDI-CAT is a reliable way to measure functional abilities in leukodystrophy, especially when clinician-administered assessments are not possible. The authors note that the PEDI-CAT is a potentially critical tool for leukodystrophy families to be able to participate in research remotely.
show less
Read the paper here.
Learn more about GLIA-CTN.
Transcript:
New research from the Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN), a research group of the Rare Diseases Clinical Research Network.
Measuring Function in Children with Leukodystrophy.
This summary is based on a paper published in the journal Developmental Medicine & Child Neurology on April 30, 2026.
Leukodystrophies are a complex, often progressive group of disorders affecting the white matter of the brain due to the loss or absence of myelin, the protective coating around nerves. Although all leukodystrophies affect neurological function, the severity and speed of progression can be very different among different types.
In this study, researchers evaluated a tool to measure function in children with leukodystrophy. Ninety-nine caregivers completed four domains (daily activities, mobility, social/cognitive, and responsibility) of a parent-reported assessment called the Pediatric Evaluation of Disability Index-Computer Adapted Test (PEDI-CAT). Researchers compared the results of the daily activities and mobility domains with clinician-administered assessments, including grasp and visual motor integrations subtests, of the Peabody Developmental Motor Scale (PDMS-2) and the 88-item Gross Motor Function Measure (GMFM-88).
Results showed a strong agreement between the PEDI-CAT and the above standard assessments. This suggests that the PEDI-CAT is a reliable way to measure functional abilities in leukodystrophy, especially when clinician-administered assessments are not possible. The authors note that the PEDI-CAT is a potentially critical tool for leukodystrophy families to be able to participate in research remotely.
Information
| Author | RDCRN |
| Organization | RDCRN |
| Website | - |
| Tags |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
Comments